Last edition
News about "Marksans Pharma"
Marksans Pharma Subsidiary Secures USFDA Approval for Loperamide Hydrochloride Tablets USP, 2 mg
Marksans Pharma's wholly owned subsidiary, Marksans Pharma Inc., has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Loperamide Hydrochloride Tablets USP, 2 mg (OTC).
Marksans Pharma | 19/11/2025 | By Dineshwori
Marksans Pharma's UK Arm Relonchem Receives UK MHRA Approval for Mefenamic Acid Tablets
Marksans Pharma announced that its wholly owned UK subsidiary, Relonchem, has received marketing authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for mefenamic acid 250 mg and 500 mg film-coated tablets. The approval further expands Relonchem’s growing footprint in the UK generics market.
Marksans Pharma | 17/11/2025 | By Dineshwori
Relonchem Gets MHRA Nod for Exemestane 25 mg Tablets
Exemestane by Relonchem, a subsidiary of Markans Pharma, is an aromatase inhibitor used in the treatment of hormone-dependent breast cancer in postmenopausal women. The approval marks another milestone in Marksans Pharma’s strategy to expand its oncology portfolio and strengthen its presence in the UK and European markets.
Marksans Pharma | 05/11/2025 | By Dineshwori | 127
Marksans Pharma's UK subsidiary Relonchem Secures MHRA Approval for Clonidine Tablets
Marksans Pharma’s wholly owned UK subsidiary, Relonchem, has received marketing authorisation from the UK Medicines & Healthcare products Regulatory Agency (MHRA) for Clonidine 100 microgram tablets and Clonidine Hydrochloride 25 microgram tablets.
Marksans Pharma | 15/10/2025 | By Dineshwori | 169
Marksans Pharma's UK Subsidiary Relonchem Secures Multiple MHRA Approvals
Marksans Pharma's wholly owned UK subsidiary, Relonchem Ltd., has received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for Metformin Hydrochloride Relonchem Prolonged Release Tablets in three strengths—500 mg, 750 mg, and 1000 mg.
Marksans Pharma | 18/08/2025 | By Dineshwori | 276
Marksans Pharma’s UK subsidiary Relonchem has received MHRA approval for Oxybutynin hydrochloride 2.5mg/5ml Oral Solution, strengthening the company’s presence in the UK generics market across key therapeutic areas.
Marksans Pharma | 19/06/2025 | By Abha | 162
Marksans Pharma completes acquisition of manufacturing site from Tevapharm India
Expand existing manufacturing capacity in India
Marksans Pharma | 20/04/2023 | By Sudeep Soparkar | 1184
Marksans Pharma announces UK MHRA approval for Fluoxetine 20mg/5ml oral solution
The product will be manufactured at the plant of Bell, Sons & Co, UK
Marksans Pharma | 24/01/2023 | By Sudeep Soparkar | 552
Marksans acquires capacity from Tevapharm India, plans to double its manufacturing footprint
The transaction is in cash consideration and is expected to be finalised by April 1, 2023, subject to the usual closing conditions
Marksans Pharma | 12/10/2022 | By Sudeep Soparkar | 1289
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy